DNA,阿尔兹海默症 z-bo 2020-09-15 372

　　A new study by researchers reveals the correlation between Alzheimer's and early changes in brain DNA methylation. DNA methylation is a biochemical change of DNA building blocks. It is a marker that indicates whether DNA is open and biologically active in a given region of the human genome.

　　According to the researchers, this is the first large-scale use of the Joint Epigenome Study (EWAS). EWAS focuses on the study of chromosome composition and changes, which are related to the brain and Alzheimer's disease.

　　"Our research methods can help better understand the biological impact and experience of environmental risk factors in Alzheimer's disease," said Dr. Philip L. De Jager, "studying the epigenome or chemical changes that occur in DNA There is an absolute advantage. The epigenome has plasticity. It will hide the occurrence of some life events, such as disease susceptibility, smoking, depression and menopause, which may affect the judgment of susceptibility to Alzheimer's disease and other diseases.

　　The researchers analyzed 708 donated brain samples and found that the brain methylation level corresponds to the 71 markers in the analysis of 7415848 CpG markers in Alzheimer's disease (this is a pair containing cytosine and guanine nucleus). DNA building blocks composed of glycosides, which are adjacent to each other). These 71 markers were found in ANK1 and RHBDF2 genes, and Alzheimer's disease is susceptible in ABCA7 and BIN1 genes.

　　Further, the investigation on CpG revealed that the RNA expression of nearby genes in Alzheimer's disease brain samples was altered: such as ANK1, CDH23, DIP2A, RHBDF2, RPL13, RNF34, SERPINF1, SERPINF2. This indicates that the function of CpG determining genes has been altered in Alzheimer's disease. "Because these findings were also found in small groups of subjects who died without cognitive impairment, it seems that these changes in DNA methylation may have played a role in the onset of Alzheimer's disease," De Jager Say. "In addition, the work of identifying regions of the human genome has changed the fate of patients with Alzheimer's disease. This provides clues to the treatment of diseases with drugs that affect epigenetic function.